Table 3.
A comparison of the incidence of relapse in exposed women and unexposed women to fertility preservation (n = 534) by adjustment in smaller calendar periods to determine an effect of treatment recommendation with adjuvant trastuzumab after Her2 screening introduced in 2005 in the Stockholm healthcare region
| Fertility preservation | Model 1a
IRR (95% CI) |
Model 2b
IRR (95% CI) |
Model 3c
IRR (95% CI) |
Model 4d
IRR (95% CI) |
|---|---|---|---|---|
| No Fertility preservation that does not require hormonal stimulation Fertility preservation that requires hormonal stimulation |
1.00 (reference)* 0.79 (0.39–1.59) 0.55 (0.31–0.98) |
1.00 (reference)* 0.85 (0.42–1.74) 0.62 (0.35–1.09) |
1.00 (reference)* 0.79 (0.38–1.61) 0.64 (0.36–1.15) |
1.00 (reference)* 0.87 (0.43–1.77) 0.63 (0.36–1.12) |
| Period of diagnosis | ||||
| 1997–2000 2001–2004 2005–2008 2009–2013 |
1.00 (reference) 0.86 (0.55–1.34) 0.44 (0.26–0.72) 0.32 (0.16–0.62) |
1.00 (reference) 0.80 (0.51–1.25) 0.41 (0.25–0.69) 0.30 (0.15–0.59) |
1.00 (reference) 0.78 (0.50–1.23) 0.39 (0.23–0.65) 0.26 (0.13–0.52) |
1.00 (reference) 0.79 (0.50–1.24) 0.42 (0.25–0.70) 0.31 (0.16–0.61) |
| Tumor size | ||||
| T0 TIS I (≤ 20 mm) II (21–50 mm) III (> 50 mm) |
0.18 (0.02–1.32) – 1.00 (reference) 1.47 (1.00–2.17) 1.32 (0.73–2.38) |
0.18 (0.02–1.30) – 1.00 (reference) 1.19 (0.77–1.84) 0.80 (0.39–1.61) |
0.17 (0.02–1.25) – 1.00 (reference) 1.53 (1.02–2.27) 1.39 (0.76–2.55) |
|
| Lymph nodes | ||||
| 0 1–3 > 3 |
1.00 (reference) 1.70 (1.12–2.59) 2.62 (1.66–4.12) |
1.00 (reference) 1.70 (1.12–2.60) 2.43 (1.52–3.88) |
1.00 (reference) 2.00 (1.26–3.18) 2.91 (1.73–4.90) |
|
| Receptors | ||||
| ER+ ER− |
1.00 (reference) 1.03 (0.69–1.52) |
1.00 (reference) 1.16 (0.77–1.74) |
||
| Neoadjuvant treatment | ||||
| No Yes |
1.00 (Reference) 2.01 (1.22–3.29) |
– | ||
| Chemotherapy | ||||
| No Yes |
1.00 (reference) 0.65 (0.37–1.14) |
CI confidence interval, IRR incidence rate ratio, ER estrogen receptor
aAdjusted for age at diagnosis (using a restricted cubic spline with 4 degrees of freedom) and the calendar period of the diagnosis
bFurther adjusted for tumor size and the number of involved lymph nodes
cFurther adjusted for estrogen receptor status and neoadjuvant treatment
dAdjusted for chemotherapy treatment (pre- or postoperative)